Results of using ophthalmic emulsion of cyclosporine A 0.05% in dry eye

Authors

  • Jaime Alemañy González Hospital Docente Clínico Quirúrgico "Hermanos Ameijeiras".
  • Belmary Aragonés Cruz Hospital Docente Clínico Quirúrgico "Hermanos Ameijeiras".
  • Franklin Dotres Hidalgo Hospital Docente Clínico Quirúrgico "Hermanos Ameijeiras".
  • Boris Luis Alfonso Guillén Hospital Docente Clínico Quirúrgico "Hermanos Ameijeiras".

Keywords:

ophthalmic emulsion of cyclosporine 0.05%, dry eye, Schirmer test

Abstract

Introduction: ophthalmic emulsion of cyclosporine 0.05% is autoimmune-modulating drug acting as a powerful immune suppressor that prevents epithelial apoptosis and cytokines production.
Objective: to evaluate the effectiveness of an ophthalmic emulsion of cyclosporine 0.05% in patients with dry eye diagnosis treated in the Ophthalmology Service at Hermanos Ameijeiras Clinical-Surgical Hospital.
Methods: descriptive and prospective observational studied in patients who attended the Oculoplastics consultation of the Ophthalmology Service at Hermanos Ameijeiras Clinical-Surgical Hospital from January to December 2012.
Results: an effective response was obtained after one-month treatment with the ophthalmic emulsion of cyclosporine 0.05%, since symptoms and signs reduced considerably and lacrimal production increased, and together with this latter, the time for breaking of the lacrimal film and Schirmer test in 73% of the cases.
Conclusions: the ophthalmic emulsion of cyclosporine 0.05% is an excellent immune-modulating drug which reduces the inflammatory process and increases lacrimal production when it is used for dry eye treatment, which considerably improves the patients’ quality of life.

Downloads

Download data is not yet available.

Author Biography

Belmary Aragonés Cruz, Hospital Docente Clínico Quirúrgico "Hermanos Ameijeiras".

Servicio Oftalmología. Hospital Clinico Quirúrgico "Hermanos Ameijeiras". San Lázaro 710 e/ Belascoaín y Marqués González, Centro Habana 10300. La Habana, Cuba. Correo electrónico: belmaryc@infomed.sld.cu

References

1. Ríos Torres M, Capote Cabrera A, Hernández Silva JR, Eguías Martínez F, Padilla González CM, et al. Oftalmología. Criterios y tendencias actuales. La Habana: ECIMED; 2009. p. 3-11.

2. Korb DR. Survey of preferred tests for diagnosis of the tears film and dry eye. Cornea. 2000;19(4):483-6.

3. Novak GD. Pharmacology treatments for dry eye: a worthwhile investment? Cornea. 2002;21(1):4-5.

4. Mathers WD. Why the eye becomes dry: a cornea and lacrimal gland feedback model. CLAO J. 2000;26(3):159-65.

5. Murube J, Benítez del Castillo JM, Chenzhuo L, Berta A, Rolando M. Triple Clasificación de Madrid para el ojo seco. Arch Soc Esp Oftalmol. 2003 Nov;78(11):595-602.

6. UreshiSalmaan H, Taylor Hugh R. Tratamiento de la enfermedad de la superficie ocular. Highlights Ophthalmol. 2001;29(6):86-95.

7. Liang H, Baudouin C, Daull P, Garrigue JS, Brignole-Baudouin F. Ocular safety of cationic emulsion of cyclosporine in an corneal wound-healing model and an acute in vivo rabbit model. Molecular Visión. 2012;18(8):2195-2204.

8. Kara N, Altinkaynak H, Goker Y, Yuksel K, Yildirim Y. Evaluation of corneal morphologic and functional parameters after use of topical cyclosporine-A 0,05 % in dry eye. J OculPharmacolTher. 2012;28(6):593-7.

9. Calonge M. The treatment of dry eye. Surv Ophthalmol. 2005;45(2).

10. Turner K, Pflugfelder SC, Ji Z, Feuer WJ, Stern M, Reis BL. Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion. Cornea. 2000;19(4):492-6.

11. Borel Jean F. History of the discovery of cyclosporin and of its early pharmacological development. Wien Klin Wochenschr. 2002;114(12):433-7.

12. Pérez-Rico C, Germain F, Castro-Rebollo M, Moreno-Salgueiro A, Teus MA. Effect of topical 0,05 % cyclosporine A on corneal endothelium in patients with dry eye disease. Int J Ophthamol. 2013;6(4):471-4.

13. Ugur Keklikci AF, Birgul Dursun BC, Abdullah Kursat Cingu CD. Topical Cyclosporine A 0,05 % Eyedrops in the Treatment of Vernal Keratoconjunctivitis– Randomized Placebo-Controlled Trial*. Adv Clin Exp Med. 2014;23(3):455-61.

14. De Paiva CS, Raince JK, McClellan AJ, Shanmugam KP, Pangelinan SB, Volpe EA, et al. Homeostatic control of conjunctival mucosal goblet cells by NKT-derived IL-13. Mucosal Inmunol. 2011;4(4):397-408.

15. Kaçmaz Oktay R, Kempen John H, Newcomb Craig, Ebenezer Daniel, Gangaputra Sapna, Nussenblatt Robert B, et al. Cyclosporine for Ocular Inflammatory Diseases. Ophthalmology. 2010;117:576-84.

16. Hamada Samer, Moore Tara CB, Moore Jonathan E, Al-Dreihi Madonna G, Anbari Anas, Shah Sunil. Assessment of the effect of cyclosporine-A 0,05 % emulsion on the ocular surface and corneal sensation following cataract surgery. Contact Lens and Anterior Eye. 2015;831:5.

17. Tok OY, Kocaoglu FA, Tok L, Burcu A, Ornek F. Treatment of ligneous conjunctivitis with amniotic membrane transplantation and topical cyclosporine. Indian J Ophthalmol. 2012; 60:563-6.

18. Arman A, Demirseren DD, Takmaz T. Treatment of ocular rosacea: comparative study of topical cyclosporine and oral doxycycline. Int J Ophthamol. 2015;8(3):544-9.

Downloads

Published

2015-11-25

How to Cite

1.
Alemañy González J, Aragonés Cruz B, Dotres Hidalgo F, Alfonso Guillén BL. Results of using ophthalmic emulsion of cyclosporine A 0.05% in dry eye. Acta Médica [Internet]. 2015 Nov. 25 [cited 2025 Mar. 14];16(2). Available from: https://revactamedica.sld.cu/index.php/act/article/view/887

Issue

Vol. 16 No. 2 (2015): Julio-Diciembre

Section

Artículos originales

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:

  1. Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
  2. Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
  3. Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).